HCW Biologics Inc. Foreign Income Tax Expense (Benefit), Continuing Operations
HCW Biologics Inc. (HCWB) reported Foreign Income Tax Expense (Benefit), Continuing Operations of $330.19 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Income Tax
us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations · last filed 2026-08-14
- HCW Biologics Inc. foreign income tax expense (benefit), continuing operations for the quarter ending 2026-06-30 was $0.00.
- HCW Biologics Inc. foreign income tax expense (benefit), continuing operations for the quarter ending 2026-03-31 was $330.19K.
| Period end | Foreign Income Tax Expense (Benefit), Continuing Operations 3 month | Foreign Income Tax Expense (Benefit), Continuing Operations 6 month |
|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q/A 3 month · filed 2026-08-14 | $330.19K 10-Q · filed 2026-08-14 |
| 2026-03-31 | $330.19K 10-Q/A · filed 2026-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| Onconetix, Inc. (ONCO) | United States | $0.004B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |